MAO-A/B-IN-3 (Compound 12) demonstrated moderate permeability in in vitro experiments, with rates recorded at 16.49 nm/s in Caco2 cells and 103.16 nm/s in MDCK cells. The compound exhibited a high plasma protein binding rate of 90.97%, indicative of strong binding, suggesting it has an extended half-life and slow excretion characteristics.

MAO-A:67 nM, MAO-B:29 nM, AChE:1370 nM

MAO-A/B-IN-3 (Compound 12) demonstrated moderate permeability in in vitro experiments, with rates recorded at 16.49 nm/s in Caco2 cells and 103.16 nm/s in MDCK cells. The compound exhibited a high plasma protein binding rate of 90.97%, indicative of strong binding, suggesting it has an extended half-life and slow excretion characteristics.

MAO-A/B-IN-3 (Compound 12), administered at a dosage of 20 mg/kg via intraperitoneal injection over 60 minutes, exhibited an increase in immobility period in test animals, suggesting its role as a central nervous system depressant. At a higher dosage of 30 mg/kg, MAO-A/B-IN-3 demonstrated significant anti-anxiety effects following a 30-minute intraperitoneal injection, with some variations of the compound showing superior efficacy compared to the reference drug Diazepam. Furthermore, administration of MAO-A/B-IN-3 at 30 mg/kg did not exhibit neurotoxic effects in male albino mice up to four hours post-injection.